Dissecting the neuronal vulnerability underpinning Alpers\u27 syndrome: A clinical and neuropathological study by Hayhurst H et al.
Brain Pathology 0 (2018) 1–17
© 2018 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the 
original work is properly cited.
1 
Brain Pathology ISSN 1015-6305
R E S E A R C H  A R T I C L E
Dissecting the neuronal vulnerability underpinning Alpers’ 
syndrome: a clinical and neuropathological study
Hannah Hayhurst1, Maria-Eleni Anagnostou1, Helen J. Bogle1, John P. Grady1, Robert W. Taylor1, 
Laurence A. Bindoff2,3, Robert McFarland1, Doug M. Turnbull1 and Nichola Z. Lax1
1 Wellcome Centre for Mitochondrial Research, Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK.  
2 Department of Clinical Medicine, University of Bergen, Bergen, Norway.  
3 Department of Neurology, Haukeland University, Bergen, Norway. 
Keywords
alpers’ syndrome, mitochondrial DNA, 
neurodegeneration, polymerase gamma, 
respiratory chain deficiency
Corresponding author: 
Nichola Lax, Wellcome Centre for 
Mitochondrial Research, Institute of 
Neuroscience, The Medical School, 
Newcastle University, Newcastle upon Tyne, 
NE2 4HH, UK (E-mail: nichola.lax@
newcastle.ac.uk)
Abbreviations:  
ANS, Ataxia neuropathy spectrum; CFV, 
Cresyl fast violet; CPEO, chronic 
progressive external ophthalmoplegia; COX, 
cytochrome c oxidase; COX1, cytochrome c 
oxidase subunit 1; COX4I2, cytochrome c 
oxidase subunit 4 isoform 2; EEG, 
electroencephalogram; FFPE, formalin-fixed 
paraffin-embedded; GAD65-67, glutamic 
acid decarboxylase 65-67; HS, hippocampal 
sclerosis; MEMSA, myoclonic epilepsy 
myopathy and sensory ataxia; MRI, 
magnetic resonance imaging; mtDNA, 
mitochondrial DNA; NDUFB8, NADH 
dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 8; NDUFA13, NADH 
dehydrogenase [ubiquinone] 1 alpha 
subcomplex 13; OD, optical density; POLG, 
polymerase-gamma; ROI, region of interest; 
SDH, succinate dehydrogenase; TLE, 
temporal lobe epilepsy.
Received 28 March 2018
published online on
29 June 2018
doi:10.1111/bpa.12640
Abstract
Alpers’ syndrome is an early-onset neurodegenerative disorder often caused by bial-
lelic pathogenic variants in the gene encoding the catalytic subunit of polymerase-
gamma (POLG) which is essential for mitochondrial DNA (mtDNA) replication. 
Alpers’ syndrome is characterized by intractable epilepsy, developmental regression 
and liver failure which typically affects children aged 6 months–3 years. Although 
later onset variants are now recognized, they differ in that they are primarily an 
epileptic encephalopathy with ataxia. The disorder is progressive, without cure and 
inevitably leads to death from drug-resistant status epilepticus, often with concomi-
tant liver failure. Since our understanding of the mechanisms contributing the neu-
rological features in Alpers’ syndrome is rudimentary, we performed a detailed and 
quantitative neuropathological study on 13 patients with clinically and histologically-
defined Alpers’ syndrome with ages ranging from 2 months to 18 years. Quantitative 
immunofluorescence showed severe respiratory chain deficiencies involving mitochon-
drial respiratory chain subunits of complex I and, to a lesser extent, complex IV 
in inhibitory interneurons and pyramidal neurons in the occipital cortex and in 
Purkinje cells of the cerebellum. Diminished densities of these neuronal populations 
were also observed. This study represents the largest cohort of post-mortem brains 
from patients with clinically defined Alpers’ syndrome where we provide quantitative 
evidence of extensive complex I defects affecting interneurons and Purkinje cells for 
the first time. We believe interneuron and Purkinje cell pathology underpins the 
clinical development of seizures and ataxia seen in Alpers’ syndrome. This study 
also further highlights the extensive involvement of GABAergic neurons in mito-
chondrial disease.
INTRODUCTION
Alpers’ syndrome, more correctly described as Alpers-
Huttenlocher syndrome, is a severe early-onset neurodegen-
erative disorder characterized by a clinical triad of intractable 
epilepsy, psychomotor regression and liver failure (2). Other 
symptoms include developmental delay, failure to thrive, 
hypotonia, spasticity and ataxia. The exact prevalence of 
Alpers’ syndrome is unknown due to high mortality and 
early death but it is estimated to affect 1:100,000 births 
(38). A bimodal disease onset has been described with the 
first peak of onset affecting infants between the ages of 6 
months and 3 years and a second peak, typified by an 
epileptic encephalopathy, during adolescence (16, 48). The 
disorder is progressive, without cure and is invariably fatal 
caused by status epilepticus or hepatic failure.
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The typical clinical presentation of Alpers’ syndrome 
is sudden explosive onset of medically refractory seizures 
in an apparently healthy and normally developing child 
or young adult. Initially, seizures may manifest as focal 
motor seizures and/or myoclonus and often progress to 
status epilepticus or focal motor status, electroenecepha-
logram (EEG) typically demonstrates a focus within the 
occipital lobe (49). Concomitant symptoms may also include 
cortical blindness, vomiting, headaches, and hemianopia. 
Cortical and thalamic involvement are seen on magnetic 
resonance imaging (MRI) and are characterized by areas 
of high intensity signal on T2 and T2-FLAIR weighted 
sequences corresponding to stroke-like lesions (44,46). 
Valproic acid was amongst a number of drugs used to 
treat the refractory epilepsy associated with Alpers’ syn-
drome until it became evident that it was precipitating 
liver failure (7).
More than 90% of cases of Alpers’ syndrome are thought 
to be due to autosomal recessive mutations in the nuclear-
encoded catalytic subunit of polymerase gamma (POLG) 
(7, 8), the sole polymerase responsible for replication and 
repair of mitochondrial DNA (mtDNA) (14). Mutations 
in POLG cause a spectrum of clinical phenotypes, includ-
ing myoclonic epilepsy myopathy and sensory ataxia 
(MEMSA), ataxia neuropathy spectrum (ANS) and both 
dominant and recessive chronic progressive external oph-
thalmoplegia (CPEO) (50). POLG defects result in either 
mtDNA depletion or accumulation of mtDNA deletions, 
and in Alpers’ syndrome it is depletion of mtDNA which 
is responsible for the development of severe mitochondrial 
respiratory chain impairments, and consequent cellular 
dysfunction and cell death in brain and liver (4, 32, 46). 
Recent whole exome sequencing has identified other molecu-
lar genetic causes of Alpers’ syndrome, including pathogenic 
mutations in FARS2 which encodes phenylalanyl-tRNA 
synthetase (10), NARS2 which encodes asparaginyl-tRNA 
synthetase and PARS2 which encodes prolyl-tRNA syn-
thetase (40, 41).
Neuropathological findings typically reveal symmetrical 
atrophy with laminar necrosis and neuronal degeneration 
affecting the cerebral cortex, hippocampi, olfactory bulbs 
and cerebellum (15, 16, 19). A recent neuropathological 
study of paediatric and adult POLG-related disease revealed 
chronic neurodegeneration with areas of acute focal neu-
ronal necrosis involving frontal, temporal and occipital 
cortices, and the hippocampus, thalamus and cerebellar 
cortex (46). Subsequent evidence has revealed focal lesions 
provide no evidence of ischaemia, suggesting this loss is 
secondary to neuronal ATP depletion caused by a com-
bination of underlying respiratory chain deficiency and 
epileptic activity increasing neuronal energy demands (45).
In the cerebellum, mild Purkinje cell loss has previously 
been documented in Alpers’ syndrome (29, 31). Diffuse 
Purkinje cell loss has been described in a cohort of adult 
patients with POLG mutations, and reduced expression 
of respiratory chain complex I has been noted in remain-
ing Purkinje cells of patients (8, 23). Numerous clinical 
and neuropathological studies reveal the occipital lobe as 
the main site of seizure genesis and a predominant area 
of neuronal degeneration in patients with Alpers’ syndrome 
(3, 11, 19, 29, 35). Extensive respiratory chain deficiency 
and interneuron loss has also been documented in occipital 
lobe tissue of patients with mitochondrial disease including 
three adult patients harboring recessively inherited POLG 
variants (22).
In the current study, we aimed to further delineate the 
pathogenesis of Alpers’ syndrome through a quantitative 
neuropathological investigation of a large series of post-
mortem brain tissues from thirteen patients with clinically-
defined Alpers’ syndrome. Our approach involved 
quantifying the extent of neuronal-subtype specific cell 
loss in conjunction with assessing evidence of mitochondrial 
respiratory chain deficiencies, involving complexes I and 
IV, in occipital cortex and the cerebellum since these areas 
often show pronounced neurodegeneration.
MATERIALS AND METHODS
Tissue material
Formalin-fixed paraffin-embedded (FFPE) brain tissue for 
the current study was acquired from the Newcastle Brain 
Tissue Resource, UK, BRAIN UK, Edinburgh Sudden 
Death Brain Bank, UK, University of Vienna, Austria, 
and University of Bergen, Norway. Where possible control 
cases were matched with our patients for age, sex, post-
mortem interval and length of tissue fixation (Supplementary 
Table 1). Not all brain regions were available for each 
patient and control and this is indicated by Supplementary 
Table 1. Ethical approval and full consent was granted 
for this work.
Immunofluorescent identification of 
mitochondrial respiratory subunits in 
interneurons, pyramidal neurons and 
Purkinje cells
Immunofluorescent assays were developed to allow iden-
tification of subunits comprising complexes I and IV rela-
tive to a mitochondrial mass marker within specific neuronal 
populations. Since there are no reliable, commercially-
available antibodies raised against mtDNA-encoded subu-
nits of complex I, commonly affected nuclear-encoded 
subunits of complex I (NADH dehydrogenase [ubiquinone] 
1 beta subcomplex subunit 8 (NDUFB8) or NADH dehy-
drogenase [ubiquinone] 1 alpha subcomplex 13 (NDUFA13)) 
were selected in conjunction with a mtDNA-encoded subunit 
of complex IV (cytochrome c oxidase subunit 1 (COX1)) 
and a marker of mitochondrial mass (porin or cytochrome 
c oxidase subunit 4 isoform 2 (COX4I2)). While there are 
no reliable histochemical methods to asses complex I activ-
ity in tissue cryosections, previous work has shown that 
complex I NDUFB8 and NDUFA13 subunits are incor-
porated at late stages of complex I assembly and are an 
essential part of functional enzymatic activity (5, 34). 
Downregulation of COX1 protein expression levels has 
been show to directly correlate to loss of COX activity 
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upon cytochrome c oxidase (COX)/succinate dehydrogenase 
(SDH) histochemistry in tissue cryosections (28). Based 
on these studies, we infer that decreased protein levels 
can reliably be interpreted as reflecting enzymatic activity. 
We have optimized and validated these antibodies exten-
sively within other studies of single muscle fibers (1, 36) 
and various brain-specific cell types in tissue sections from 
patients with mitochondrial disease (8, 13, 22).
In occipital lobe tissue, these antibodies were used in 
conjunction with neuronal markers; anti-SMI-32P an anti-
body that recognizes non-phosphorylated neurofilaments 
in pyramidal neurons and anti-glutamic acid decarboxylase 
65-67 (GAD65-67) an antibody that identifies GABAergic 
interneurons. The combinations of primary antibodies were 
selected on the basis of different IgG subtypes. Due to 
an overlap in IgG1 isotype for SMI-32P and NDUFB8 
two triple-labeled assays were used: the first to identify 
complex I, mitochondria and pyramidal neurons and the 
second to identify complex IV, mitochondria and pyramidal 
neurons. These assays were applied to 8 patients and 4 
controls were FFPE occipital lobe tissue was available. 
In the cerebellum, porin was used to define the Purkinje 
cell body due to their characteristic morphology therefore 
the assay did not utilize a neuronal marker; this was 
applied to 9 patients and 8 controls. All primary and 
secondary antibodies used are listed in Supplementary 
Table 2. A no primary antibody (NPA) section was included 
alongside patients and controls for each brain region.
Immunofluorescence was performed on 5 μm FFPE brain 
sections as previously described (12, 22). This briefly involved 
deparaffinization and rehydration of the sections followed 
by antigen retrieval and blocking in 10% goat serum for 
an hour. Primary antibodies were incubated overnight at 
4°C, the following day and where applicable IgG 
 subtype-specific biotinylated goat anti-mouse antibodies 
were applied to amplify either NDUFB8 or NDUFA13 
antibody signal which has previously been shown to be 
weak. Sections were incubated for 2 h at 4°C, sections 
were washed with TBST and the appropriate IgG subtype-
specific secondary anti-mouse or anti-rabbit antibodies 
conjugated with Alexa Fluor 405, 488, 546 and 647 anti-
bodies applied for 2 h at 4°C (see Supplementary Table 
2). When possible the sections were incubated with Hoescht 
(Sigma Aldrich; diluted 1:1200 with TBST) for 20 minutes 
at room  temperature to label nuclei. All sections were 
incubated in 0.3% Sudan Black for 10 minutes to eliminate 
any  autofluorescence. This was followed by washing in 
distilled water and mounting in Prolong Gold (Life 
Technologies, UK).
Confocal microscopy
Neurons were imaged using a confocal microscope (Nikon 
A1R, UK). Neurons were detected using an immersion oil 
×60 objective with numerical aperture 1.4 by their SMI-
32P or GAD65-67-positive signal. At least 40 neurons were 
randomly sampled per case using an electronic zoom of 
×3.09. Purkinje cells in the cerebellum were detected using 
a ×20 objective on the basis of their porin signal and 
imaged at the same magnification. Microscope and laser 
settings were maintained throughout image capture.
Image processing and analysis
Neurons were identified and manually outlined according 
to the presence of either GAD65-67 405 nm (for interneu-
rons), SMI-32P 647 nm (for pyramidal neurons) or porin 
546 nm (for Purkinje cells) fluorescent signal using Volocity 
software (PerkinElmer); this defined the region of interest 
(ROI). For each neuron, the mean optical densities (OD) 
of each mitochondrial respiratory complex subunit 
(NDUFB8, NDUFA13 or COX1) and mitochondrial mass 
marker (porin or COX4I2) were measured within the defined 
ROI and subject to background correction from NPA 
section.
The control group was created by sampling equal 
numbers of neurons from each control subject and pool-
ing the background corrected mean OD values. Box-Cox 
transformation identified the log transformation as opti-
mal to normalise the data. Linear regression of trans-
formed NDUFB8 (NDUFB8T) data against transformed 
porin (porinT) data, transformed NDUFA13 (NDUFA13T) 
data against transformed COX4I2 (COX4I2T) data and 
transformed COX1 (COX1T) data against porinT data 
were performed to ensure the residuals of the regression 
were normally distributed. NDUFB8T, NDUFA13T and 
COX1T values were then corrected for mitochondrial 
mass by dividing by the appropriate mitochondrial mass 
marker (porinT or COX4I2T). In order to derive z-scores 
for each pyramidal neuron, interneuron and Purkinje 
cell the mass-corrected NDUFA13 (NDUFA13Z), 
NDUFB8 (NDUFB8Z) and COX1 (COX1Z) values were 
calculated based on the parameters (mean and standard 
deviation) of the control group. Neurons were classified 
based on standard deviation (SD) limits (for NDUFA13Z, 
NDUFB8Z or COX1Z: overexpression if z > 2SD, normal 
if z  > -2SD, low if z  <  -2SD, deficiency if z  <  -3SD 
and severe deficiency if z  < -4SD) and are presented 
as percentages to give the proportion of cells within 
each SD limit.
Statistical analysis
All statistical analyses were carried out using GraphPad 
Prism 7.0 (GraphPad Software, Inc., La Jolla, California). 
To determine statistical significant changes in complex I 
or IV protein expression in each patient relative to the 
control group, median z scores for each patient and con-
trol were compared using an unpaired t-test. To determine 
changes in porin or COX4I2, the mean OD per neuron 
in patient and control tissues was compared using a 
Mann–Whitney U test. To ascertain a correlation between 
neuronal cell loss, complex I or IV deficiency and age 
at death, Spearman rank correlation coefficient was per-
formed. A significant P-value cut off was taken at 
*P  ≤  0.05, **P ≤  0.01 and ***P ≤  0.001.
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Neurohistopathological staining
Immunohistochemistry for identification of pyramidal neu-
rons (anti-SMI-32P; Covance 1:6,000) and interneurons 
(anti-GAD65-67; Sigma 1:6,000) using a polymer detection 
kit and visualization with DAB as previously described 
(24). 20μm sections of FFPE cerebellar tissue were stained 
with cresyl fast violet (CFV) allowing identification of 
Purkinje cells.
Two-dimensional neuronal cell quantification
A two-dimensional neuronal cell counting protocol was 
employed using a modified light microscope (Olympus 
BX51), motorized stage for automatic sampling, CCD colour 
video and stereology software (StereoInvestigator, MBF 
Bioscience, Williston, VT) as previously described (22, 23). 
This briefly involved outlining an area of at least 10μm2 
along the cortical ribbon for the occipital cortex encom-
passing cellular layers I–VI at ×2 magnification. Within 
this area GAD65-67-positive interneurons and SMI-32P-
positive pyramidal neurons in occipital lobe tissues were 
counted at ×20 magnification. Purkinje cell density was 
calculated by identifying the Purkinje cell layer using the 
closed contour function of StereoInvestigator, accounting 
for their linear arrangement. Purkinje cells with a visible 
nucleolus were counted within this, and density calculated. 
Neuronal cell densities were calculated as number per mm2. 
Since only one measurement was provided per patient and 
control case, and due to the low numbers in each group, 
it was not possible to perform statistical analysis of neu-
ronal cell density data.
RESULTS
Clinical features
In total thirteen patients with clinically-determined Alpers’ 
syndrome were investigated and a diagnosis of Alpers’ 
syndrome was made on the basis of the presence of refrac-
tory seizures/status epilepticus, psychomotor regression 
and/or liver failure (Table  1). A bimodal onset of Alpers’ 
syndrome is apparent with patients 1–10 and 12 developing 
symptoms early in infancy while patients 11 and 13 devel-
oped symptoms in later childhood. Seizures (including 
status epilepticus, epilepsia partialis continua or generalized 
seizures) were a major feature in all thirteen patients, and 
the presenting symptom in patients 2, 3, 5, 7, 8 and 13. 
Symptoms preceding seizure onset often included head-
aches, vomiting and visual abnormalities (including visual 
hallucinations and visual blindness). Other symptoms 
included psychomotor regression (delayed motor develop-
ment, loss of previously acquired skills, minimal respon-
siveness) and liver failure affecting six patients.
Molecular genetic diagnosis was achieved for five patients 
and Sanger sequencing confirmed the presence of mutated 
POLG variants (Table  1). Of these five patients; two har-
bored p.Ala467Thr/p.Gly848Ser, one harbored 
p.Gly303Arg/p.Ala467Thr, one harbored p.Ala467Thr/p.
Thr914Pro and the final patient harbored homozygous 
p.Trp748Ser/p.Trp748Ser variants. Unfortunately genetic 
diagnosis has not been possible for the remaining eight 
patients since they died prior to genetic testing for POLG 
defects and extraction of DNA from fixed tissues did not 
allow for successful PCR amplification for screening of 
the three common variants associated with POLG-related 
disease.
Four patients harboring biallelic POLG mutations have 
been previously reported; the clinical, genetic and neuro-
pathological findings described for patients 4 and 6 by 
Tzoulis and colleagues (46), the clinical course and muscle 
biochemistry reported for patient 8 by Morris and col-
leagues (30) and the clinical and neuropathological findings 
reported for patient 10 by Jellinger and colleagues (17).
Gross neuropathological findings
The gross neuropathological findings from post-mortem 
are summarized by Table  2. The most common findings 
were significant atrophy affecting the cerebral hemispheres 
and focal areas of cortical depressions corresponding to 
areas of cortical laminar dehiscence caused by neuronal 
necrosis. Typically the occipital, parietal and cerebellar 
cortices were affected by severe, focal pan-necrotic lesions 
featuring profound neuronal cell loss and a strong astro-
cytic response. These findings are compatible with previous 
descriptions in the literature (15, 45, 46).
Respiratory chain deficiency in interneurons 
and pyramidal neurons
Quantitative quadruple-labeled immunofluorescence showed 
co-localization of NDUFB8, COX1 and porin within control 
interneurons and pyramidal neurons. In both the occipital 
lobe and cerebellum, patient neurons showed a significantly 
higher mean OD of porin per cell than control neurons 
(Mann–Whitney U test, P  <  0.0001) suggesting that mito-
chondrial mass was much higher in patient neurons.
Interneurons in the occipital cortex of patients exhibited 
significant downregulation of NDUFB8 (unpaired t-test, 
P < 0.0001) and COX1 (unpaired t-test, P < 0.0005) protein 
expression relative to mitochondrial mass marker porin 
(Figure  1A). In all patients a high proportion of interneu-
rons demonstrated severe complex I deficiency (Figure  1Bi) 
while complex IV deficiency was more variable, with only 
patients 4 (p.Ala467Thr/p.Gly848Ser), 6 (p.Gly303Arg/p.
Ala467Thr), 7 (pAla467Thr/p.Gly848Ser) and 10 
(p.Thr748Ser/p.Thr748Ser) demonstrating severe complex IV 
deficiency in comparison to other patients (Figure  1Bii). 
All patient interneurons expressed complex I subunit 
NDUFB8 below the normal limits indicating that all 
interneurons exhibited severely deficient, deficient and low 
levels of NDUFB8 expression. While for complex IV subunit 
COX1 only two patients; patient 4 (p.Ala467Thr/p.Gly848Ser) 
and patient 6 (p.Gly303Arg/p.Ala467Thr), revealed down-
regulation of COX1 within all interneurons.
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Patient pyramidal neurons in the occipital cortex also 
demonstrated marked deficiency of NDUFA13 (unpaired 
t-test, P  =  0.0358; Figure  2A,B). However, this is likely 
an underestimation of complex I deficiency since com-
parison of COX4I2 OD (which is used as a mitochondrial 
mass marker in this assay) in patient and control neurons 
revealed a lower density of COX4I2 expression in neurons 
implying a loss of this protein in patient neurons. 
Significant downregulation of COX1 expression levels in 
patient pyramidal neurons was also observed (unpaired 
t-test, P  <  0.0063; Figure  3A,B). All patients showed 
high percentages of both complex I-deficient and severely 
deficient neurons (Figure  2B). Patient 11 showed severe 
complex I deficiency in all neurons examined. Patient 
neurons showed milder complex IV deficiencies, with the 
most extensive deficiency being seen in patient 11 
(Figure  3B).
Respiratory chain deficient Purkinje cells of 
the cerebellum
The Purkinje cells in cerebellar cortex of patients exhib-
ited decreased respiratory chain protein expression for 
both complexes I and IV (Figure  4). All patient Purkinje 
cells demonstrated a significant downregulation of com-
plex I relative to control subjects (unpaired t-test, 
Figure 1. Downregulation of NDUFB8 and COX1 expression levels in patient GAD65-67-positive interneurons in occipital cortex. Representative 
images reveal downregulation of NDUFB8 and COXI expression levels relative to mitochondrial mass marker porin in patient inhibitory interneurons 
A. Scale bar = 10 microns. Quantitative analysis reveals the mitochondrial respiratory chain expression profiles for each patient and confirms higher 
percentage levels of NDUFB8 (unpaired t-test, P < 0.0001) B.i. and COXI (unpaired t-test, P < 0.0005) B.ii. deficiencies in interneurons.
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P  =  0.0002) with patients 1, 2, 12 and 13 exhibiting the 
highest levels of complex I deficiency in Purkinje cells. 
Complex IV expression was variable, and comparison of 
patient vs. control median z values revealed a significant 
downregulation in the patient cohort (unpaired t-test, 
P < 0.0064), although only patients 3 and 8 (p.Ala467Thr/p.
Thr914Pro) revealed neurons with complex IV 
deficiency.
Neuronal loss in Alpers’ syndrome
The consequence of respiratory chain deficiency was inves-
tigated by quantification of GABAergic and pyramidal 
neuronal cell densities in the occipital cortex and Purkinje 
cell density in the cerebellar cortex. The grey matter corti-
cal ribbon demonstrated atrophy, with laminar dehiscence 
observed in patients 4 (p.Ala467Thr/p.Gly848Ser), 6 
(p.Gly303Arg/p.Ala467Thr), 8 (p.Ala467Thr/p.Thr914Pro), 
Figure 2. Downregulation of NDUFA13 expression levels in patient SMI-32P-positive pyramidal neurons within the occipital cortex. Representative 
images showing downregulation of complex I subunit NDUFA13 expression levels relative to complex IV subunit COX4I2 in pyramidal neurons from 
patients with Alpers’ syndrome A. Scale bar = 10 microns. Quantitative analysis reveals the mitochondrial respiratory chain expression profiles for 
each patient and confirms varying percentages of NDUFA13 deficiency in SMI-32P-positive pyramidal neurons (unpaired t-test, P = 0.0358) B.
Neurodegeneration and Alpers’ syndrome Hayhurst et al
Brain Pathology 0 (2018) 1–17
© 2018 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology
10
9, 11–13, characterized by neuronal dropout and spongy 
changes affecting all cortical layers. To understand the 
pattern of neuronal dropout, quantification of interneurons 
and pyramidal neuronal cell densities was performed. 
Quantification revealed reduced densities of both interneu-
rons (Figure  5A) and pyramidal neurons (Figure  5B) 
throughout patient cortical layers relative to controls sug-
gestive of interneuron and pyramidal neuron loss. Neuronal 
loss did not correlate with either complex I or complex 
IV deficiency in interneurons or pyramidal neurons, nor 
did it correlate with age (Spearman rank correlation 
coefficient).
The cerebellar cortex was atrophic in patients relative 
to controls, with a fewer Purkinje cells observed in the 
majority of cases (Figure  6Aii). An area of focal neuronal 
necrosis, consistent with a stroke-like lesion, was seen in 
patient 13 (Figure  6Aiv). In other patients, Purkinje cells 
were selectively affected, with no apparent loss of granular 
cells or cells in the molecular layer on visual assessment. 
Quantification of Purkinje cell density revealed lower 
Figure 3. Downregulation of COX1 expression levels in patient SMI-32P-positive pyramidal neurons within the occipital cortex. Representative 
images showing downregulation of complex IV subunit COXI relative to mitochondrial mass marker porin in pyramidal neurons from patients with 
Alpers’ syndrome A. Scale bar = 10 microns. Quantification of protein expression in pyramidal neurons shows varying percentages of complex IV 
deficiency (unpaired t-test, P < 0.0063) B.
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densities in patient cerebellum (Figure  6B) relative to con-
trols. Purkinje cell loss did not correlate with age or with 
complex I or IV deficiency in surviving Purkinje cells 
(Spearman rank correlation coefficient).
DISCUSSION
Epilepsy, developmental regression and liver involvement 
are the classical features of Alpers’ syndrome. Due to the 
fulminant epilepsy, this syndrome is associated with poor 
prognosis and a rapidly progressive disease course. In the 
current study, epilepsy was a salient feature in all patients, 
and the presenting symptom in six. Although epilepsy is 
common in Alpers’ syndrome, the mechanisms underlying 
seizure generation and maintenance remain unclear. Using 
a novel quantitative approach, we investigated the develop-
ment of neuronal respiratory chain deficiency and cell loss 
in a large cohort of patients with clinically defined Alpers’ 
syndrome. In particular, we focused on potential mecha-
nisms contributing to seizures. We showed that occipital 
cortex GABAergic interneurons and pyramidal neurons, 
as well as Purkinje cells in the cerebellum, exhibited 
Figure 4. Downregulation of NDUFB8 and COX1 expression levels in patient Purkinje cells in the cerebellum. Representative images of 
immunofluorescent labeling of respiratory chain proteins NDUFB8, COXI and porin in Purkinje cells provide evidence of reduced NDUFB8 and COX1 
expression despite intact mitochondria density (porin) in patient tissues A. Scale bar = 100 microns. Quantitation of the protein abundance provides 
mitochondrial respiratory chain profiles for each individual patient given as the percentage of complex I (NDUFB8; B.i, unpaired t-test, P = 0.0002) 
and IV (COX1; B.ii, unpaired t-test, P < 0.0064) expression in Purkinje cells.
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Figure 5. Decreased numbers of cortical inhibitory interneuron and pyramidal neurons in occipital cortex from patients with Alpers’ syndrome relative 
to control subjects. Immunohistochemical staining reveals GAD65-67-positive inhibitory interneurons in control (A. i; control 7) and fewer GAD65-67-
positive interneurons in occipital cortex tissue from patients with Alpers’ syndrome (A.ii; patient 7). Scale bar = 100 microns. Quantification of 
GAD65-67 cell density confirms a reduction in GABAergic interneuron density in Alpers’ syndrome (A. iii); patient = red bars, control = blue bars). 
Immunohistochemical staining reveals SMI-32P-positive pyramidal neurons in control (A. i; control 5) and reduced immunoreactivity for SMI-32P and 
fewer SMI-32P-positive cells in Alpers’ syndrome (B. ii; patient 5).  Scale bar = 100 microns. Quantification provides evidence of decreased pyramidal 
cell density in Alpers’ syndrome (B. iii; red bars = patients, blue bars = controls).
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Figure 6. Purkinje cell density is reduced in patients with Alpers’ syndrome. Cresyl fast violet staining reveals the architecture of the cerebellar cortex 
in control (Ai; control 3) and shows Purkinje cell dropout in a patient with Alpers’ syndrome (Aii; patient 1). A comparison of age-match control (Aiii: 
control 6) with an 18 year old patient with Alpers’ syndrome due to POLG mutations reveals a focal necrotic lesion featuring profound Purkinje cell 
and granule cell loss and destruction of the neuropil (Aiv; patient 13). Scale bar = 100 microns.  Quantification of Purkinje cell density (B; red bars = 
patients, blue bars = controls) confirms reduced density in patients with Alpers’ syndrome.
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extensive respiratory chain defects as evidenced by sig-
nificant downregulation of complex I subunit proteins and 
milder downregulation of complex IV subunit proteins. 
This was despite evidence of maintained or increased 
mitochondrial mass which could represent a compensatory 
response. Although loss of interneurons and pyramidal 
cells was similar, the magnitude of respiratory chain defi-
ciency was more pronounced in interneurons raising the 
possibility that the loss of inhibitory neural networks plays 
a role in the seizure development in these patients.
A major limitation of this study is the absence of a 
confirmed genetic diagnosis for eight of our patients due 
a lack of availability of suitable tissues for molecular 
genetic testing. Unfortunately many of these cases are 
historical and precede the development of sequencing tech-
nologies to identify the causative genes for Alpers’ syn-
drome. Our criteria for inclusion of patient tissues was 
dependent on a clinical disease course and histopathological 
changes consistent with Alpers’ syndrome.
Occipital lobe vulnerability in Alpers’ 
syndrome
The occipital lobe appears to be the main site for seizure 
genesis in Alpers’ syndrome and visual disturbances are 
also frequently described in both paediatric and adult 
patients harboring POLG mutations. Such visual phenom-
ena, include flickering light, hallucinations, or loss of vision 
(11) and similar symptoms were described in seven of our 
patients. In this study, we confirm pathology affecting the 
occipital cortex with evidence of cortical atrophy, micro-
vacuolation, and areas of focal neuronal necrosis in seven 
out of nine patients. We for the first time demonstrated 
quantitative evidence of extensive involvement of cortical 
interneurons in patients with Alpers’ syndrome. This study 
supports a vulnerability of GABAergic interneurons to 
mtDNA defects in patients with mitochondrial disease and 
is in agreement with a recent study revealing similar find-
ings in a cohort of adult patients with mitochondrial disease 
(22). Unfortunately due to limited tissue availability, it 
was not possible to ascertain whether the severity and 
type of pathological changes were restricted to the occipital 
lobes and it will be important to extend these investiga-
tions to other cortical regions in Alpers’ syndrome in 
future studies.
Cerebellar vulnerability in Alpers’ syndrome
In addition to the clear occipital involvement, we show a 
reduction in Purkinje cell density and respiratory chain 
defects, affecting subunits of complexes I and IV, in Alpers’ 
syndrome. This is a novel albeit unsurprising finding given 
ataxia is common in both paediatric and adult patients 
with this syndrome. Reduced Purkinje cell density com-
bined with compromised respiratory chain protein expres-
sion has previously been documented in adult patients 
with mitochondrial disease, including those with POLG 
mutations (8,23).
Cerebellar atrophy and Purkinje cell loss are common 
histological changes in patients with epilepsy (9, 37) and 
many develop ataxia (51). The specific mechanisms under-
pinning this pathology are unknown, however it could be 
attributed to seizure activity, particular status epilepticus 
(42) or due to toxicity of anti-convulsants, such as phenytoin 
(9, 25, 26, 33). It is challenging to determine the precise 
mechanism by which the cerebellum is affected since both 
mechanisms may act synergistically. Unfortunately, we are 
unable to comment on phenytoin use in our patient cohort 
due to the scarcity of clinical information, however given 
the short-nature of the disease, and extensive respiratory 
chain deficiency in remaining Purkinje cells we think it 
unlikely that the pathology is primarily caused by anti-
convulsant toxicity.
Neuron-specific pathology
Our data show GABAergic interneurons and pyramidal 
neurons of the occipital cortex, and Purkinje cells in the 
cerebellum exhibit extensive respiratory chain defects with 
significant downregulation of complex I subunit proteins 
coupled with milder downregulation of complex IV subunit 
proteins despite evidence of maintained or increased mito-
chondrial mass. These findings provide further support 
for the hypothesis that focal neuronal loss seen in POLG-
related stroke-like lesions is a consequence of intrinsic 
neuronal energy failure rather than ischaemia (45). The 
consequence of the complex I deficiency within neurons 
we report in Alpers’ syndrome is not well understood, 
however the findings here support suggestions that complex 
I deficiency could be a contributory factor in the develop-
ment of epilepsy (20).
Quantitative analysis of neuronal density showed sig-
nificantly reduced densities of interneurons and pyramidal 
neurons in the occipital lobe, and reduced Purkinje cell 
density in the cerebellum in patients relative to controls. 
Previous studies have highlighted areas of focal cortical 
necrosis in the pathogenesis of Alpers’ syndrome; a finding 
observed in seven patients in this study (46). In the remain-
ing six patients, neuronal loss appeared widespread through-
out the occipital and cerebellar cortices. This could suggest 
two independent mechanisms of neurodegeneration are 
contributing to the pathology observed in Alpers’ 
syndrome.
Our findings of severe respiratory chain defects and 
loss of interneurons in the occipital lobes of our patients 
are novel and potentially offer the first clue to what may 
be driving the epilepsy in this disease. Epilepsy often 
heralds the rapid deterioration in patients with Alpers’ 
syndrome, and it was the only common symptom in all 
13 patients in our cohort. It is striking, therefore, that 
patients 2, 4, 5 and 7 exhibited deficiency of complex I 
in all surviving occipital interneurons examined. Further, 
while neuropathological studies are limited by the fact 
that tissue demonstrates end-stage disease, it is remarkable 
that in all patients in whom occipital lobe tissue was 
studied, there were no normal interneurons remaining. 
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Recent electrophysiological studies have revealed a specific 
vulnerability of fast-spiking interneurons to mitochondrial 
respiratory chain inhibitors, rotenone and potassium cya-
nide, which function to block complex I and IV activity 
(18, 47). Since interneurons often function as modulators 
of cortical neuron activity, the loss of any inhibitory activ-
ity could potentially lead to a lower seizure threshold and 
increase the probability of neuronal network becoming 
hyperexcitable. Indeed a specific pattern of inhibitory 
interneuron loss is reported in other epileptic disorders, 
such as temporal lobe epilepsy (TLE)/hippocampal sclerosis 
(HS), and experimental models of seizures and these altera-
tions may contribute to sustained imbalances in excitatory/
inhibitory activity which might perpetuate seizure activity 
in the brain (21, 27). Qualitative and quantitative altera-
tions in specific inhibitory interneuron populations in TLE/
HS tend to involve those expressing calcium binding pro-
teins such as calbindin, calretinin and parvalbumin 
(6, 39, 43) and this specific vulnerability of interneurons 
should be explored in the context of Alpers’ syndrome.
Alpers’ syndrome is a rapidly progressive, incurable 
neurodegenerative disease and patients often die before 3 
years of age. We present a detailed neuropathological 
characterization of post-mortem tissue from thirteen 
patients that provides quantitative evidence of extensive 
complex I defects affecting interneurons and Purkinje cells. 
This is the most complete study to date and details the 
role of interneurons and how cell loss in both occipital 
lobes and cerebellum contribute to the pathogenesis of 
the seizures and ataxia.
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